KA/EN
Register
Medicines reference
Search
Search
Active substance

Afoxolaner

Favourites

Isoxazoline ectoparasiticide. Registered in Georgia: 5 veterinary products. Forms: chewable tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Afoxolaner
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2.5–6.94 mg/kg Dog Maintenance By mouth monthly
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
NexGard Spectra 9 mg / 2 mg chewable tablets for dogs 1.35-3.5 kg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning (Dog)
    In the absence of available data, treatment of puppies less than 8 weeks of age and dogs less than 1.35 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. The safety of NexGard has not been evaluated in dogs less than 8 weeks of age or less than 4 lbs body weight.
    Sources: VMD SPC · VMD · FDA
  • Caution (Dog)
    Afoxolaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Neurological signs (convulsion, ataxia and muscle tremor).
    Sources: VMD SPC · VMD · FDA
Latin name
Afoxolaner
Georgian name
აფოქსოლანერი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
5 of 9 forms
Products
NexGard, NexGard Spectra
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration9

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

NexGard 11 mg, Chewable tablet

afoxolaner 11.3 mg, chewable tablet for dogs 2-4 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

NexGard

11 mg, afoxolaner 11.3 mg, chewable tablet for dogs 2-4 kg
Assessed clinical scopeDog · Full dog label: fleas, listed tick species, indirect reduction of Dipylidium caninum and Babesia canis transmission risk, use in a flea-allergy dermatitis strategy, demodicosis, sarcoptic mange and ear mites within the exact tablet weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment after exact weighing, parasite confirmation or individual epidemiological risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective, well documented monthly canine ectoparasiticide with unusually broad current mite and vector-risk label claims. Strong foreign authorisation does not change its absence from the Georgian register, and exact whole-tablet selection plus neurologic counselling remain important.

Regulatory and scientific credibility8.5/10

The exact strength is supported by a current detailed 2026 VMD SPC and active EU, UK and US authorisations. Afoxolaner-only NexGard is explicitly not registered in the checked Georgian veterinary register, unlike NexGard Spectra or Combo.

Clinical efficacy9.2/10

A large year-long field comparison supports high monthly flea and tick control, while direct controlled or multicentre field studies support demodicosis, sarcoptic mange and ear-mite roles. Vector-risk reductions are indirect and parasites must feed, so transmission cannot be excluded.

Safety and tolerability8.0/10

Labelled adverse events are very rare and mostly mild, short and self-limiting, but vomiting, diarrhoea, lethargy, anorexia, pruritus and isoxazoline-associated convulsion, ataxia or tremor require counselling. Young or underweight puppies and breeding males need benefit-risk assessment.

Clinical practicality9.0/10

One palatable chewable each month, directly or with food, is operationally simple; pregnancy and lactation use is permitted. Accurate whole-tablet band selection is essential, tablets cannot be divided, and mite indications require diagnosis-specific follow-up rather than automatic monthly use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with hypersensitivity to afoxolaner or an excipient. This product is labelled for dogs, not cats.
  • Below 8 weeks of age or 2 kg, use only after the responsible veterinarian documents a benefit-risk assessment. Use in pregnant or lactating dogs and breeding females is permitted; breeding males still require benefit-risk assessment.
  • Counsel for vomiting, diarrhoea, lethargy, anorexia, pruritus, convulsion, ataxia or muscle tremor. Labelled events are very rare and mostly mild, short and self-limiting, but marked or persistent signs require reassessment.
  • Fleas, ticks and mites must begin feeding, so parasite-borne transmission cannot be excluded. Confirm parasite or epidemiological risk, address infested household animals and avoid unnecessary use or underdosing that can select resistance.
  • For fleas and listed ticks, use at monthly intervals according to season, local epidemiology and lifestyle. The label gives indirect Dipylidium-risk reduction for 30 days and Babesia canis-risk reduction for 28 days; neither is a guarantee against infection.
  • For demodicosis, continue until two negative skin scrapings one month apart and address underlying disease; for sarcoptic mange, give two monthly doses and extend only by clinical assessment and scrapings; for ear mites, give one dose and re-examine after one month.
  • Weigh accurately and use one whole 11 mg tablet only at 2-4 kg. Do not divide the tablet.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard EPAR2026
  3. Georgia NFA register 20262026
  4. NexGard yearly field comparator2024
  5. Afoxolaner demodicosis field study2018
  6. Afoxolaner sarcoptic field RCT2016
  7. Afoxolaner ear-mite field RCT2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner11.3 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-406
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard 28 mg, Chewable tablet

afoxolaner 28.3 mg, chewable tablet for dogs >4-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

NexGard

28 mg, afoxolaner 28.3 mg, chewable tablet for dogs >4-10 kg
Assessed clinical scopeDog · Full dog label: fleas, listed tick species, indirect reduction of Dipylidium caninum and Babesia canis transmission risk, use in a flea-allergy dermatitis strategy, demodicosis, sarcoptic mange and ear mites within the exact tablet weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment after exact weighing, parasite confirmation or individual epidemiological risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective, well documented monthly canine ectoparasiticide with unusually broad current mite and vector-risk label claims. Strong foreign authorisation does not change its absence from the Georgian register, and exact whole-tablet selection plus neurologic counselling remain important.

Regulatory and scientific credibility8.5/10

The exact strength is supported by a current detailed 2026 VMD SPC and active EU, UK and US authorisations. Afoxolaner-only NexGard is explicitly not registered in the checked Georgian veterinary register, unlike NexGard Spectra or Combo.

Clinical efficacy9.2/10

A large year-long field comparison supports high monthly flea and tick control, while direct controlled or multicentre field studies support demodicosis, sarcoptic mange and ear-mite roles. Vector-risk reductions are indirect and parasites must feed, so transmission cannot be excluded.

Safety and tolerability8.0/10

Labelled adverse events are very rare and mostly mild, short and self-limiting, but vomiting, diarrhoea, lethargy, anorexia, pruritus and isoxazoline-associated convulsion, ataxia or tremor require counselling. Young or underweight puppies and breeding males need benefit-risk assessment.

Clinical practicality9.0/10

One palatable chewable each month, directly or with food, is operationally simple; pregnancy and lactation use is permitted. Accurate whole-tablet band selection is essential, tablets cannot be divided, and mite indications require diagnosis-specific follow-up rather than automatic monthly use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with hypersensitivity to afoxolaner or an excipient. This product is labelled for dogs, not cats.
  • Below 8 weeks of age or 2 kg, use only after the responsible veterinarian documents a benefit-risk assessment. Use in pregnant or lactating dogs and breeding females is permitted; breeding males still require benefit-risk assessment.
  • Counsel for vomiting, diarrhoea, lethargy, anorexia, pruritus, convulsion, ataxia or muscle tremor. Labelled events are very rare and mostly mild, short and self-limiting, but marked or persistent signs require reassessment.
  • Fleas, ticks and mites must begin feeding, so parasite-borne transmission cannot be excluded. Confirm parasite or epidemiological risk, address infested household animals and avoid unnecessary use or underdosing that can select resistance.
  • For fleas and listed ticks, use at monthly intervals according to season, local epidemiology and lifestyle. The label gives indirect Dipylidium-risk reduction for 30 days and Babesia canis-risk reduction for 28 days; neither is a guarantee against infection.
  • For demodicosis, continue until two negative skin scrapings one month apart and address underlying disease; for sarcoptic mange, give two monthly doses and extend only by clinical assessment and scrapings; for ear mites, give one dose and re-examine after one month.
  • Weigh accurately and use one whole 28 mg tablet only above 4 kg through 10 kg. Do not divide the tablet.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard EPAR2026
  3. Georgia NFA register 20262026
  4. NexGard yearly field comparator2024
  5. Afoxolaner demodicosis field study2018
  6. Afoxolaner sarcoptic field RCT2016
  7. Afoxolaner ear-mite field RCT2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner28.3 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-406
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard 68 mg, Chewable tablet

afoxolaner 68 mg, chewable tablet for dogs >10-25 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

NexGard

68 mg, afoxolaner 68 mg, chewable tablet for dogs >10-25 kg
Assessed clinical scopeDog · Full dog label: fleas, listed tick species, indirect reduction of Dipylidium caninum and Babesia canis transmission risk, use in a flea-allergy dermatitis strategy, demodicosis, sarcoptic mange and ear mites within the exact tablet weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment after exact weighing, parasite confirmation or individual epidemiological risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective, well documented monthly canine ectoparasiticide with unusually broad current mite and vector-risk label claims. Strong foreign authorisation does not change its absence from the Georgian register, and exact whole-tablet selection plus neurologic counselling remain important.

Regulatory and scientific credibility8.5/10

The exact strength is supported by a current detailed 2026 VMD SPC and active EU, UK and US authorisations. Afoxolaner-only NexGard is explicitly not registered in the checked Georgian veterinary register, unlike NexGard Spectra or Combo.

Clinical efficacy9.2/10

A large year-long field comparison supports high monthly flea and tick control, while direct controlled or multicentre field studies support demodicosis, sarcoptic mange and ear-mite roles. Vector-risk reductions are indirect and parasites must feed, so transmission cannot be excluded.

Safety and tolerability8.0/10

Labelled adverse events are very rare and mostly mild, short and self-limiting, but vomiting, diarrhoea, lethargy, anorexia, pruritus and isoxazoline-associated convulsion, ataxia or tremor require counselling. Young or underweight puppies and breeding males need benefit-risk assessment.

Clinical practicality9.0/10

One palatable chewable each month, directly or with food, is operationally simple; pregnancy and lactation use is permitted. Accurate whole-tablet band selection is essential, tablets cannot be divided, and mite indications require diagnosis-specific follow-up rather than automatic monthly use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with hypersensitivity to afoxolaner or an excipient. This product is labelled for dogs, not cats.
  • Below 8 weeks of age or 2 kg, use only after the responsible veterinarian documents a benefit-risk assessment. Use in pregnant or lactating dogs and breeding females is permitted; breeding males still require benefit-risk assessment.
  • Counsel for vomiting, diarrhoea, lethargy, anorexia, pruritus, convulsion, ataxia or muscle tremor. Labelled events are very rare and mostly mild, short and self-limiting, but marked or persistent signs require reassessment.
  • Fleas, ticks and mites must begin feeding, so parasite-borne transmission cannot be excluded. Confirm parasite or epidemiological risk, address infested household animals and avoid unnecessary use or underdosing that can select resistance.
  • For fleas and listed ticks, use at monthly intervals according to season, local epidemiology and lifestyle. The label gives indirect Dipylidium-risk reduction for 30 days and Babesia canis-risk reduction for 28 days; neither is a guarantee against infection.
  • For demodicosis, continue until two negative skin scrapings one month apart and address underlying disease; for sarcoptic mange, give two monthly doses and extend only by clinical assessment and scrapings; for ear mites, give one dose and re-examine after one month.
  • Weigh accurately and use one whole 68 mg tablet only above 10 kg through 25 kg. Do not divide the tablet.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard EPAR2026
  3. Georgia NFA register 20262026
  4. NexGard yearly field comparator2024
  5. Afoxolaner demodicosis field study2018
  6. Afoxolaner sarcoptic field RCT2016
  7. Afoxolaner ear-mite field RCT2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner68 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-406
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard 136 mg, Chewable tablet

afoxolaner 136 mg, chewable tablet for dogs >25-50 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

NexGard

136 mg, afoxolaner 136 mg, chewable tablet for dogs >25-50 kg
Assessed clinical scopeDog · Full dog label: fleas, listed tick species, indirect reduction of Dipylidium caninum and Babesia canis transmission risk, use in a flea-allergy dermatitis strategy, demodicosis, sarcoptic mange and ear mites within the exact tablet weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment after exact weighing, parasite confirmation or individual epidemiological risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective, well documented monthly canine ectoparasiticide with unusually broad current mite and vector-risk label claims. Strong foreign authorisation does not change its absence from the Georgian register, and exact whole-tablet selection plus neurologic counselling remain important.

Regulatory and scientific credibility8.5/10

The exact strength is supported by a current detailed 2026 VMD SPC and active EU, UK and US authorisations. Afoxolaner-only NexGard is explicitly not registered in the checked Georgian veterinary register, unlike NexGard Spectra or Combo.

Clinical efficacy9.2/10

A large year-long field comparison supports high monthly flea and tick control, while direct controlled or multicentre field studies support demodicosis, sarcoptic mange and ear-mite roles. Vector-risk reductions are indirect and parasites must feed, so transmission cannot be excluded.

Safety and tolerability8.0/10

Labelled adverse events are very rare and mostly mild, short and self-limiting, but vomiting, diarrhoea, lethargy, anorexia, pruritus and isoxazoline-associated convulsion, ataxia or tremor require counselling. Young or underweight puppies and breeding males need benefit-risk assessment.

Clinical practicality9.0/10

One palatable chewable each month, directly or with food, is operationally simple; pregnancy and lactation use is permitted. Accurate whole-tablet band selection is essential, tablets cannot be divided, and mite indications require diagnosis-specific follow-up rather than automatic monthly use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with hypersensitivity to afoxolaner or an excipient. This product is labelled for dogs, not cats.
  • Below 8 weeks of age or 2 kg, use only after the responsible veterinarian documents a benefit-risk assessment. Use in pregnant or lactating dogs and breeding females is permitted; breeding males still require benefit-risk assessment.
  • Counsel for vomiting, diarrhoea, lethargy, anorexia, pruritus, convulsion, ataxia or muscle tremor. Labelled events are very rare and mostly mild, short and self-limiting, but marked or persistent signs require reassessment.
  • Fleas, ticks and mites must begin feeding, so parasite-borne transmission cannot be excluded. Confirm parasite or epidemiological risk, address infested household animals and avoid unnecessary use or underdosing that can select resistance.
  • For fleas and listed ticks, use at monthly intervals according to season, local epidemiology and lifestyle. The label gives indirect Dipylidium-risk reduction for 30 days and Babesia canis-risk reduction for 28 days; neither is a guarantee against infection.
  • For demodicosis, continue until two negative skin scrapings one month apart and address underlying disease; for sarcoptic mange, give two monthly doses and extend only by clinical assessment and scrapings; for ear mites, give one dose and re-examine after one month.
  • Weigh accurately and use one whole 136 mg tablet only above 25 kg through 50 kg. Do not divide the tablet. Above 50 kg, use a veterinarian-selected combination of whole tablets.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard EPAR2026
  3. Georgia NFA register 20262026
  4. NexGard yearly field comparator2024
  5. Afoxolaner demodicosis field study2018
  6. Afoxolaner sarcoptic field RCT2016
  7. Afoxolaner ear-mite field RCT2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner136 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-406
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard Spectra 9 mg/2 mg, Chewable tablet

afoxolaner 9.375 mg + milbemycin oxime 1.875 mg, chewable tablet for dogs 1.35-3.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

9 mg/2 mg, afoxolaner 9.375 mg + milbemycin oxime 1.875 mg, chewable tablet for dogs 1.35-3.5 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 40-11, 453-11, 173-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner9.375 mg Milbemycin oxime1.875 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა - 2-3,5კგ ძაღლებისთვის
№ 40-11, 453-11, 173-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard Spectra 19 mg/4 mg, Chewable tablet

afoxolaner 18.75 mg + milbemycin oxime 3.75 mg, chewable tablet for dogs 3.5-7.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

19 mg/4 mg, afoxolaner 18.75 mg + milbemycin oxime 3.75 mg, chewable tablet for dogs 3.5-7.5 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 41-11, 351-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner18.75 mg Milbemycin oxime3.75 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->3,5-7,5კგ ძაღლებისთვის
№ 41-11, 351-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard Spectra 38 mg/8 mg, Chewable tablet

afoxolaner 37.5 mg + milbemycin oxime 7.5 mg, chewable tablet for dogs 7.5-15 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

38 mg/8 mg, afoxolaner 37.5 mg + milbemycin oxime 7.5 mg, chewable tablet for dogs 7.5-15 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 42-11, 452-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner37.5 mg Milbemycin oxime7.5 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->7,5-15კგ ძაღლებისთვის
№ 42-11, 452-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard Spectra 75 mg/15 mg, Chewable tablet

afoxolaner 75 mg + milbemycin oxime 15 mg, chewable tablet for dogs 15-30 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

75 mg/15 mg, afoxolaner 75 mg + milbemycin oxime 15 mg, chewable tablet for dogs 15-30 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 43-11, 352-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner75 mg Milbemycin oxime15 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->15-30კგ ძაღლებისთვის
№ 43-11, 352-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard Spectra 150 mg/30 mg, Chewable tablet

afoxolaner 150 mg + milbemycin oxime 30 mg, chewable tablet for dogs 30-60 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

150 mg/30 mg, afoxolaner 150 mg + milbemycin oxime 30 mg, chewable tablet for dogs 30-60 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 19-11, 338-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner150 mg Milbemycin oxime30 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა - >30-60კგ ძაღლებისთვის
№ 19-11, 338-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗